Compare PHG & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHG | IQV |
|---|---|---|
| Founded | 1891 | 1982 |
| Country | Netherlands | United States |
| Employees | 65340 | 93000 |
| Industry | Medical Electronics | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 28.6B |
| IPO Year | N/A | 2013 |
| Metric | PHG | IQV |
|---|---|---|
| Price | $29.14 | $174.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $227.13 |
| AVG Volume (30 Days) | 942.3K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 7.84 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $2.79 | $6.78 |
| Revenue Next Year | $4.47 | $5.88 |
| P/E Ratio | $28.46 | ★ $21.98 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $21.95 | $134.65 |
| 52 Week High | $33.44 | $247.05 |
| Indicator | PHG | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 53.66 |
| Support Level | $26.44 | $159.42 |
| Resistance Level | $29.41 | $193.26 |
| Average True Range (ATR) | 0.50 | 6.19 |
| MACD | 0.32 | 1.26 |
| Stochastic Oscillator | 96.24 | 74.73 |
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.